Attributes | Values |
---|
rdf:type
| |
description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2007 (ast)
- наукова стаття, опублікована в серпні 2007 (uk)
- scientific article published on 28 August 2007 (en)
- مقالة علمية نشرت في 28 أغسطس 2007 (ar)
- գիտական հոդված հրատարակված 2007 թվականի օգոստոսի 28-ին (hy)
|
publication date
| |
publication date
| |
language of work or name
| |
language of work or name
| |
cites work
| |
cites work
| - Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus
- Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group
- Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
- The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans
- A role for immune complexes in enhanced respiratory syncytial virus disease
- The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
- An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
- Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine
- Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population
- Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children
- Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
- Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
- Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
- Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate
- Pathogenesis of respiratory syncytial virus infection in the murine model
- Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene
- Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials
- A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes
- Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.
- Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
|
author name string
| |
author name string
| - Peter L Collins
- Peter F Wright
- Alice F O'Shea
- Jian R Shi
- Valerie B Randolph
|
rdfs:label
| - The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (en)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (nl)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (ast)
|
skos:prefLabel
| - The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (en)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (nl)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (ast)
|
name
| - The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (en)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (nl)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (ast)
|
author
| |
author
| |
title
| |
title
| - The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |